Livzon Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Livzon Pharmaceutical Group Inc (000513.CS)

Q3 202623 Jul – 29 Sep 2026

▲2▼1

Livzon profit slumps on price cuts, but new drug approvals build pipeline

First-half profit and revenue drop sharply Livzon's first-half net profit fell 27.2% to 932 million yuan and revenue dropped 20.3% to 5 billion yuan. Chemical drug sales fell 25% on medical insurance price cuts and national volume-based procurement, while TCM sales fell 35% as flu demand faded. This weak earnings picture is the main drag on the stock.
The profit decline is the single biggest force pushing the stock down this period.
New leuprorelin three-month microsphere approval Shanghai Livzon won approval for an 11.25mg three-month leuprorelin acetate microsphere injection, a Category B insurance-listed drug for breast cancer, prostate cancer and precocious puberty. It is the only domestic maker of this dosage form, in a market worth about 10.9 billion yuan where three-month forms are 27%.
A genuinely new, exclusive product approval that can add future revenue and offsets the weak earnings.
New TCM granule approval enriches product line Livzon's Sichuan Guangda unit received a drug registration certificate for Banxia Baizhu Tianma Decoction Granules, its first Category 3.1 new traditional Chinese medicine. The approval adds to the product pipeline, though the company gave no launch timing or sales forecast, so the near-term financial benefit is limited.
A new product approval that supports the pipeline story, though small in scale.
Parent Joincare's weak finances and guarantee load Parent Joincare disclosed a 2.069 billion yuan guarantee balance, including guarantees for Livzon units, while its 2025 and first-quarter revenue and profit both fell. This adds a modest financial-risk overhang, though the guarantees are not overdue and Livzon's own operating cash flow actually rose 4.5%.
Shows the parent-level financial backdrop and guarantee exposure that color sentiment on Livzon.

August 202623 Jul – 29 Sep 2026

▲2▼1

Livzon profit slumps on price cuts, but new drug approvals build pipeline

First-half profit and revenue drop sharply Livzon's first-half net profit fell 27.2% to 932 million yuan and revenue dropped 20.3% to 5 billion yuan. Chemical drug sales fell 25% on medical insurance price cuts and national volume-based procurement, while TCM sales fell 35% as flu demand faded. This weak earnings picture is the main drag on the stock.
The profit decline is the single biggest force pushing the stock down this period.
New leuprorelin three-month microsphere approval Shanghai Livzon won approval for an 11.25mg three-month leuprorelin acetate microsphere injection, a Category B insurance-listed drug for breast cancer, prostate cancer and precocious puberty. It is the only domestic maker of this dosage form, in a market worth about 10.9 billion yuan where three-month forms are 27%.
A genuinely new, exclusive product approval that can add future revenue and offsets the weak earnings.
New TCM granule approval enriches product line Livzon's Sichuan Guangda unit received a drug registration certificate for Banxia Baizhu Tianma Decoction Granules, its first Category 3.1 new traditional Chinese medicine. The approval adds to the product pipeline, though the company gave no launch timing or sales forecast, so the near-term financial benefit is limited.
A new product approval that supports the pipeline story, though small in scale.
Parent Joincare's weak finances and guarantee load Parent Joincare disclosed a 2.069 billion yuan guarantee balance, including guarantees for Livzon units, while its 2025 and first-quarter revenue and profit both fell. This adds a modest financial-risk overhang, though the guarantees are not overdue and Livzon's own operating cash flow actually rose 4.5%.
Shows the parent-level financial backdrop and guarantee exposure that color sentiment on Livzon.

Latest23 Jul – 29 Sep 2026

▲2▼1

Livzon profit slumps on price cuts, but new drug approvals build pipeline

First-half profit and revenue drop sharply Livzon's first-half net profit fell 27.2% to 932 million yuan and revenue dropped 20.3% to 5 billion yuan. Chemical drug sales fell 25% on medical insurance price cuts and national volume-based procurement, while TCM sales fell 35% as flu demand faded. This weak earnings picture is the main drag on the stock.
The profit decline is the single biggest force pushing the stock down this period.
New leuprorelin three-month microsphere approval Shanghai Livzon won approval for an 11.25mg three-month leuprorelin acetate microsphere injection, a Category B insurance-listed drug for breast cancer, prostate cancer and precocious puberty. It is the only domestic maker of this dosage form, in a market worth about 10.9 billion yuan where three-month forms are 27%.
A genuinely new, exclusive product approval that can add future revenue and offsets the weak earnings.
New TCM granule approval enriches product line Livzon's Sichuan Guangda unit received a drug registration certificate for Banxia Baizhu Tianma Decoction Granules, its first Category 3.1 new traditional Chinese medicine. The approval adds to the product pipeline, though the company gave no launch timing or sales forecast, so the near-term financial benefit is limited.
A new product approval that supports the pipeline story, though small in scale.
Parent Joincare's weak finances and guarantee load Parent Joincare disclosed a 2.069 billion yuan guarantee balance, including guarantees for Livzon units, while its 2025 and first-quarter revenue and profit both fell. This adds a modest financial-risk overhang, though the guarantees are not overdue and Livzon's own operating cash flow actually rose 4.5%.
Shows the parent-level financial backdrop and guarantee exposure that color sentiment on Livzon.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.